Diagnostic challenges in distinguishing TRALI from COVID-19 ARDS
Eurasian Journal of Anesthesiology and Intensive Care · 16.05.2026 · 3 (2) · 23-26
DOI: 10.51271/eajaic-0053 ↗Kurz gefasst
Fachartikel in der Zeitschrift Eurasian Journal of Anesthesiology and Intensive Care, online erschienen am 16.05.2026. Verfasst von Zeynep Koç und 3 weiteren Autor:innen.
Abstract (Originalsprache)
Severe acute respiratory syndrome caused by the SARS-CoV-2 virus (COVID-19) presents with a wide spectrum of clinical manifestations, ranging from asymptomatic infection to acute respiratory distress syndrome (ARDS) and multiorgan failure. Transfusion-related acute lung injury (TRALI) is a serious complication of blood transfusion and is associated with significant morbidity and mortality. A 46-year-old male patient with known chronic kidney disease presented to the emergency department with dyspnea and cough. The patient oxygen saturation was 78%. Laboratory findings revealed elevated white blood cell count, C-reactive protein, and D-dimer levels, along with lymphopenia; hemoglobin level was 7.3 g/dL. Chest computed tomography demonstrated diffuse bilateral ground-glass opacities with focal areas of consolidation. The patient was monitored in the intensive care unit with nasal oxygen therapy. Following blood transfusion for anemia, respiratory status deteriorated at the sixth hour post-transfusion, necessitating endotracheal intubation and initiation of mechanical ventilation. The deterioration in the patient’s respiratory status requiring mechanical ventilation was attributed to several differential diagnoses, including ARDS secondary to COVID-19 or other microorganisms, TRALI, and transfusion-associated circulatory overload (TACO). Bedside chest radiography demonstrated bilateral diffuse pulmonary opacities. Transthoracic echocardiography showed no evidence of left atrial hypertension (LAH), thereby excluding TACO. Accordingly, in our patient, who had risk factors for ARDS but a stable respiratory status for 36 hours before transfusion, the diagnosis of Type II TRALI was considered. The patient was successfully extubated on day 9. Repeated SARS-CoV-2 PCR tests and rapid antibody tests were negative, and blood and urine cultures showed no growth. The patient was discharged to the ward on day 20. TRALI may develop even in the presence of risk factors for ARDS. For the differential diagnosis of TRALI, TACO, and ARDS, a comprehensive evaluation using clinical findings, laboratory parameters, and objective criteria such as echocardiography is recommended.
Zitieren
APA
Koç, Z., Silay, E., Gür, A., & Aydoğan, S. (2026). Diagnostic challenges in distinguishing TRALI from COVID-19 ARDS. Eurasian Journal of Anesthesiology and Intensive Care, 3(2), 23-26. https://doi.org/10.51271/eajaic-0053
Vancouver
Koç Z, Silay E, Gür A, Aydoğan S. Diagnostic challenges in distinguishing TRALI from COVID-19 ARDS. Eurasian Journal of Anesthesiology and Intensive Care. 2026;3(2):23-26. doi:10.51271/eajaic-0053
BibTeX
@article{Ko2026,
author = {Koç, Zeynep and Silay, Emin and Gür, Abdullah and Aydoğan, Serhat},
title = {Diagnostic challenges in distinguishing TRALI from COVID-19 ARDS},
journal = {Eurasian Journal of Anesthesiology and Intensive Care},
year = {2026},
volume = {3},
number = {2},
pages = {23--26},
doi = {10.51271/eajaic-0053}
}
EUVIMED